No connection

Search Results

AVTR vs HALO

AVTR
Avantor, Inc.
BEARISH
Price
$11.80
Market Cap
$8.05B
Sector
Healthcare
AI Confidence
85%
HALO
Halozyme Therapeutics, Inc.
NEUTRAL
Price
$67.82
Market Cap
$8.03B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
AVTR
--
HALO
26.49
Forward P/E
AVTR
12.97
HALO
6.92
P/B Ratio
AVTR
1.44
HALO
163.82
P/S Ratio
AVTR
1.22
HALO
5.75
EV/EBITDA
AVTR
10.78
HALO
11.18

Profitability

Gross Margin
AVTR
33.13%
HALO
77.79%
Operating Margin
AVTR
8.48%
HALO
56.31%
Profit Margin
AVTR
-1.25%
HALO
22.69%
ROE
AVTR
-1.48%
HALO
153.59%
ROA
AVTR
3.43%
HALO
22.24%

Growth

Revenue Growth
AVTR
-5.3%
HALO
51.6%
Earnings Growth
AVTR
--
HALO
--

Financial Health

Debt/Equity
AVTR
0.69
HALO
44.6
Current Ratio
AVTR
1.49
HALO
4.66
Quick Ratio
AVTR
0.88
HALO
3.3

Dividends

Dividend Yield
AVTR
--
HALO
--
Payout Ratio
AVTR
0.0%
HALO
0.0%

AI Verdict

AVTR BEARISH

The Advanced Deterministic Scorecard reveals significant financial weakness with a Piotroski F-Score of just 2/9, indicating poor profitability, deteriorating margins, and weak operating performance. Despite a reasonable Debt/Equity ratio and positive operating cash flow proxies, the company is unprofitable on a net basis (negative net margin and ROE), with declining revenue and earnings. Insider selling, a bearish technical trend, and a sharp multi-year price decline further reinforce deterioration in fundamentals. Although the forward P/E of 12.97 appears low, weak execution, shrinking profits, and lack of intrinsic value benchmarks suggest the market is pricing in continued challenges.

Strengths
Forward P/E of 12.97 suggests potential undervaluation relative to sector average P/E of 202.93
Operating margin remains healthy at 8.48%, indicating pricing power or cost control at operational level
Debt/Equity ratio of 0.69 is below sector average of 2.31, suggesting conservative capital structure
Risks
Piotroski F-Score of 2/9 signals severe financial distress and high risk of continued underperformance
Negative net profit margin (-1.25%) and negative ROE (-1.48%) indicate systemic profitability issues
Revenue declining YoY by 5.30% and EPS down 15.4% YoY point to deteriorating fundamentals
HALO NEUTRAL

HALO presents a stark contrast between operational efficiency and valuation sanity. While the Piotroski F-Score of 4/9 indicates stable financial health, the stock trades at a massive premium to its Graham Number ($4.88) and Intrinsic Value ($17.92). Despite exceptional operating margins (56.31%) and strong revenue growth (51.6%), the recent collapse in EPS (-114% Q/Q) and aggressive insider selling by the CEO and COO create significant headwinds that offset the bullish analyst consensus.

Strengths
Exceptional profitability with 77.79% gross margins and 56.31% operating margins
Strong top-line momentum with 51.60% YoY revenue growth
Very high Return on Equity (153.59%) indicating efficient capital use
Risks
Extreme valuation disconnect with a Price/Book ratio of 163.82
Severe recent earnings deterioration (EPS growth -122.6% YoY)
Bearish insider sentiment with significant selling by the CEO and COO

Compare Another Pair

AVTR vs HALO: Head-to-Head Comparison

This page compares Avantor, Inc. (AVTR) and Halozyme Therapeutics, Inc. (HALO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile